

# A high-throughput qPCR system for flexible and cost-effective large panel assay testing

**Mukesh Maharjan, Ph.D.**

Scientist, PCR applications and enzymology

# Overview

1

## Why molecular methods of detection?

Traditional vs. molecular methods

2

## Why large panels?

Need for high-throughput qPCR system

3

## Large panel example

Comprehensive UTI combo panel  
(96 assays)

Spike-in control and its advantages

4


## Workflow for SmartChip ND<sup>®</sup> system

5

## Summary

# Molecular methods for pathogen detection preferred over traditional methods

## Traditional bacterial culture



### Primary challenges

Long turnaround time (>24–48 hr)

Limited targets

Lower sensitivity

Limited detection of AMR\* genes

Costly in the long term

### Key benefits

Fast turnaround time (3 hr)


Comprehensive detection

Higher sensitivity

Larger coverage of AMR genes

Cheaper in the long term

## Molecular methods: PCR/qPCR



### Additional benefits

- ✓ Detection of novel pathogens
- ✓ Smaller sample volumes
- ✓ Surveillance capability
- ✓ Characterization of infectious agents
- ✓ Epidemiological benefits


\*Antimicrobial Resistance

### References

- Gu et al. Molecular diagnostics for infectious diseases: Novel approaches, clinical applications and future challenges. *Frontiers in Microbiology* (2023).
- Pfaller. Molecular approaches to diagnosing and managing infectious diseases: practicality and costs. *Emerging Infectious Diseases* (2001).
- Schmitz et al. Forty years of molecular diagnostics for infectious diseases. *Journal of Clinical Microbiology* (2022).

# Large panels provide more information

## Small panel



### Primary challenges

Detects limited number of species

Inadequate for detecting rare species that cause a large portion of UTIs

Insufficient for detecting most AMR genes

High likelihood of incomplete information

### Key benefits


Faster detection

Results for more species

Broader scope of detection

More complete information

## Large panel



### Additional benefits


- ✓ Improved accuracy and sensitivity
- ✓ Increased efficiency and decreased costs

### References

- Upadhyay et al. [Expanded PCR Panel Testing for Identification of Respiratory Pathogens and Coinfections in Influenza-like Illness](#). *Diagnostics (Basel)* (2023).




# Why high-throughput qPCR?



# SmartChip ND Real-Time PCR System


High-throughput pathogen detection made easy

Nanowell chip




5,184 (100 nl)  
reactions/chip

SmartChip ND



<1 hr sample and  
assay dispense

SmartChip ND Cyclor



~2 hr qPCR run  
to data

# Case-study: wound, UTI, and STI panel

## Wound

1. *Bacteroides fragilis*
2. *Kingella kingae*
3. *Streptococcus pyogenes*
4. AAC (6')-Ib
5. AAC (6')-Ib-cr
6. ANT (3'')-IIa/aadA
7. APH (3')-VIa
8. ermA
9. ermB
10. mefA
11. tetM

## UTI


- |                                     |                                         |                   |               |                   |
|-------------------------------------|-----------------------------------------|-------------------|---------------|-------------------|
| 1. <i>Acinetobacter baumannii</i>   | 18. <i>Klebsiella oxytoca</i>           | 36. blaACC        | 54. blaOXA-48 | 72. vanB          |
| 2. <i>Actinobaculum schaalii</i>    | 19. <i>Klebsiella pneumoniae</i>        | 37. blaACT/blaMIR | 55. blaOXA-72 | 73. vanC          |
| 3. <i>Aerococcus urinae</i>         | 20. <i>Morganella morganii</i>          | 38. blaCMY        | 56. blaPER-1  | 74. <u>Alien</u>  |
| 4. <i>Bacillus atrophaeus</i>       | 21. <i>Mycoplasma hominis</i>           | 39. blaCTX-M 1    | 57. blaPER-2  | 75. <u>RNaseP</u> |
| 5. <i>Candida albicans</i>          | 22. <i>Proteus mirabilis</i>            | 40. blaCTX-M 2    | 58. blaSHV    | 76. <u>16s</u>    |
| 6. <i>Candida auris</i>             | 23. <i>Proteus vulgaris</i>             | 41. blaCTX-M 8/25 | 59. blaTEM    |                   |
| 7. <i>Candida glabrata</i>          | 24. <i>Providencia stuartii</i>         | 42. blaCTX-M 9    | 60. blaVEB    |                   |
| 8. <i>Candida parapsilosis</i>      | 25. <i>Pseudomonas aeruginosa</i>       | 43. blaDHA        | 61. blaVIM    |                   |
| 9. <i>Candida tropicalis</i>        | 26. <i>Serratia marcescens</i>          | 44. blaFOX        | 62. dfrA1     |                   |
| 10. <i>Citrobacter freundii</i>     | 27. <i>Staphylococcus aureus</i>        | 45. blaGES        | 63. dfrA5     |                   |
| 11. <i>Citrobacter koseri</i>       | 28. <i>Staphylococcus epidermidis</i>   | 46. blaIMP-1      | 64. mecA      |                   |
| 12. <i>Corynebacterium riegelii</i> | 29. <i>Staphylococcus haemolyticus</i>  | 47. blaIMP-7      | 65. nfsA      |                   |
| 13. <i>Enterobacter aerogenes</i>   | 30. <i>Staphylococcus lugdunensis</i>   | 48. blaIMP-16     | 66. QnrA      |                   |
| 14. <i>Enterobacter cloacae</i>     | 31. <i>Staphylococcus saprophyticus</i> | 49. blaKPC        | 67. QnrB      |                   |
| 15. <i>Enterococcus faecalis</i>    | 32. <i>Streptococcus agalactiae</i>     | 50. blaMOX        | 68. QnrS      |                   |
| 16. <i>Enterococcus faecium</i>     | 33. <i>Streptococcus anginos</i>        | 51. blaOXA-1      | 69. sul1      |                   |
| 17. <i>Escherichia coli</i>         | 34. <i>Streptococcus oralis</i>         | 52. blaOXA-23     | 70. sul2      |                   |
|                                     | 35. <i>Ureaplasma urealyticum</i>       | 53. blaOXA-40     | 71. vanA      |                   |

## STI

1. *Candida dubliniensis*
2. *Chlamydia trachomatis*
3. *Haemophilus ducreyi*
4. HSVI
5. HSV2
6. *Mycoplasma genitalium*
7. *Neisseria gonorrhoeae*
8. *Treponema pallidum*
9. *Trichomonas vaginalis*

Legend: Fungus Parasite Virus Bacteria Antibiotic resistance gene Control

# Integrating in silico design and assay validation




**Data  
retrieval**

Relevant strain information collected from databases such as GISAID, GenBank, and whole-genome sequencing (WGS) repositories




**Strain  
filtering**

Based on  
clade classification  
and date of collection  
to ensure up-to-date  
and relevant coverage



**Assay  
filtering**

Based on sequence alignment to guarantee strain inclusivity, exclusivity, and adherence to qPCR design criteria, thus preventing non-specific amplification



**Primer and  
probe validation**

Final forward and reverse primers, along with FAM-labeled probes, were selected for laboratory testing



# Rigorous in-lab testing

**1** Selection of assays with the best  $R^2$ , efficiency, and S-curve

**2** Inclusivity test with proficiency panel

**3** Exclusivity test with nearest-neighbor species

**4** Validated with human samples

# Comprehensive UTI combo panel (96 assays)

Comprehensive  
detection  
across multiple  
targets is a  
growing need!

## Broad target coverage = more accurate information

- Avoid misidentification and retesting delays
- Quickly identify antibiotic resistance

## Better controls = higher reliability

- Process validation from extraction to detection
- Assurance of data quality → true negative vs. false negative
- Alien spike-in control → process control with non-homologous sequence
- RNaseP → internal control
- 16S → bacteria load control
- *Bacillus atrophaeus* → extraction control

# Growing need for AMR detection worldwide

## United States

### Since 2013

- Over  $2 \times 10^6$  illnesses caused by AR bacteria
- More than 23,000 deaths due to antibiotic resistant (AR) bacteria

### California

- >50% of urinary tract infections (UTIs) due to bacteria resistant to  $\geq 1$  antibiotic class
- ~13% of UTIs resistant to  $\geq 3$  antibiotic classes

## South Korea

75% of *Acinetobacter* isolates in blood showed resistance

## Malawi


Nearly 100% of *N. gonorrhoeae* isolates were resistant to ceftriaxone, with 15% resistant to azithromycin

### Source

- Van Beusekom. Data show rising antibiotic resistance with repeat urinary tract infections. Center for Infectious Disease Research and Policy. 2024.

# Alien spike-in control

- To monitor entire molecular detection workflow
- 1 kb exogenous sequence non-homologous to human, mouse, or human-pathogen genome sequences
- Generation of shortest common super-sequence (SCS)
  - Bioinformatics to create an algorithm (avoid repeat sequences)
  - Result: nonrepetitive 1 kb sequence packed with “alien” subsequences





## Choose your spike-in control



- ✓ DNA version
- ✓ RNA version with virus-like particles (VLPs)

# Advantages of alien spike-in control

## Process control



## No cross reactivity






# Workflow for UTI, STI, and wound panel


IsoPure Mini or IsoPure 96




Sample prep



Nanodispensing




PCR



Data analysis

Duplex reaction to monitor full qPCR workflow (including extraction)



FAM


HEX

Sample **assay** does not cross-react with control


Control in the **same** well

**SIGNIFICANT  
ADVANTAGE!**

**Confidence  
in each  
sample/result**





# Best performing assays were selected



- Each assay tested in singleplex and duplex formats
- Excellent efficiency (Eff) and R<sup>2</sup> values

Distribution of 96 assays



# Achieved required sensitivity


All 96 assays were very sensitive and can detect as low as 10 copies per reaction

- 20–40 replicates tested for the calculation
- Limit of Detection (LoD) criteria: target detected for  $\geq 95\%$  of replicates

<i>Acinetobacter baumannii</i>	<i>Citrobacter freundii</i>	<i>Klebsiella aerogenes</i>	<i>Pseudomonas aeruginosa</i>	<i>Streptococcus oralis</i>	blaCTX-M 9	blaMOX	blaSHV*	QnrA	<i>Candida dubliniensis</i>	<i>Trichomonas vaginalis</i>	ermB
<i>Actinotignum schaalii</i>	<i>Citrobacter koseri</i>	<i>Klebsiella oxytoca</i>	<i>Serratia marcescens</i>	<i>Ureaplasma urealyticum</i>	blaDHA	blaOXA-1	blaTEM	QnrB	<i>Chlamydia trachomatis</i>	<i>Bacteroides fragilis</i>	mefA
<i>Aerococcus urinae</i>	Coagulase-negative staphylococci (CoNS)	<i>Klebsiella pneumoniae</i>	<i>Staphylococcus aureus</i>	blaACC	blaFOX	blaOXA-23	blaVEB	QnrS	<i>Haemophilus ducreyi</i>	<i>Kingella kingae</i>	tetM
<i>Candida albicans</i>	<i>Corynebacterium riegelii</i>	<i>Metamycoplasma hominis</i>	<i>Staphylococcus epidermidis</i>	blaACT	blaGES	blaOXA-40*	blaVIM*	sul1	<i>Herpes simplex virus type 1</i>	AAC(6')-Ib	<i>Bacillus atrophaeus</i>
<i>Candida auris</i>	<i>Enterobacter cloacae</i>	<i>Morganella morganii</i>	<i>Staphylococcus haemolyticus</i>	blaCMY	blaIMP-1	blaOXA-48	dfrA1	sul2	<i>Herpes simplex virus type 2</i>	AAC(6')-Ib-cr	16S*
<i>Candida glabrata</i>	<i>Enterococcus faecalis</i>	<i>Proteus mirabilis</i>	<i>Staphylococcus saprophyticus</i>	blaCTX-M 1	blaIMP-7	blaOXA-72	dfrA5	vanA	<i>Mycoplasma genitalium</i>	ANT(3'')-IIa	RNaseP
<i>Candida parapsilosis</i>	<i>Enterococcus faecium</i>	<i>Proteus vulgaris</i>	<i>Streptococcus agalactiae</i>	blaCTX-M 2	blaIMP-16	blaPER-1	mecA	vanB	<i>Neisseria gonorrhoeae</i>	APH(3')-VIa	
<i>Candida tropicalis</i>	<i>Escherichia coli</i>	<i>Providencia stuartii</i>	<i>Streptococcus anginosus</i>	blaCTX-M 8	blaKPC	blaPER-2	nfsA	vanC	<i>Treponema pallidum</i>	ermA	

\* Four assays (including 16S and  $\beta$ -lactam) were detected at  $\leq 50$  copies per reaction.






# Advantages of the SmartChip ND System



# Advantages of the SmartChip ND system



## Scalability

- Can handle large panels
- Ideal for small to larger lab facilities




## Automated workflow

- Less human error
- Better reproducibility
- Less hands-on time




Lower cost  
per reaction



## Flexibility

- Customizable assays and sample combinations
- Can be used for any assay panel (not just UTI)



Low reagent  
consumption



# Flexible panels to fit your application needs

## Examples of molecular assays

High-throughput SARS-CoV-2 testing  
6 assays/panel = 768 samples/chip

Nail fungus pathogen panel (21 assays)

UTI panel ( $\leq 72$  assays)

TaKaRa UTI plus panel (96 assays)

Highly parallel ARG detection panel (384 assays)

	Samples/chip	
Small panel	6	768
	12	384
	24	216
	36	144
	48	108
	54	96
	72	72
	80	64
	96	54
	120	42
	144	36
	216	24
Large panel	248	20
	296	16
	384	12

### References

- Stedtfeld et al. Primer set 2.0 for highly parallel qPCR array targeting antibiotic resistance genes and mobile genetic elements. *FEMS Microbiology Ecology* (2018).

# Reduced reagent and time consumption

**Less reagents + Less time = More savings**

## 5,184 reactions on SmartChip ND vs. plates

Category	384-well plate (10 µl rxn)	SCND	Fold difference
Master mix	>30 ml	<0.5 ml	>60
Assay mix	>3 ml	~100 µl	>30
Turnaround time	~25 hr	~4 hr	>6




**60-fold reagent savings**  
compared to traditional plate-based qPCR



Turn around time is  
**6 times faster**


# Long term cost savings

**Less reagents + Less time = More savings**




# Highly consistent results at a large scale

## Highly comparable variability



# Reproducible and accurate results within a run




Enclosed, humidified environment and chip cooling station ensure thermal uniformity.

**Highly reproducible gene expression data.** A single assay run was performed with input from a single sample. The Ct values range from 19.36–19.96, with a low standard deviation (<0.1).



# Confidence in genotype clusters

**Robust calling for sample concentrations as low as 1 ng/ $\mu$ l**



**The SmartChip ND system provides highly accurate and sensitive detection, which is critical for making calls when genotyping.** Multiple 1 ng/ $\mu$ l samples (**Panel A**) and 5 ng/ $\mu$ l samples (**Panel B**) were run on the SmartChip ND system using the same genotyping assay. Although the 1 ng/ $\mu$ l samples are more diffuse, the clustering still enables calling.

# Summary

- Growing demand for larger pathogen detection panels
  - qPCR a better option than culture-based methods
- SmartChip ND system for high throughput qPCR
  - Significant time and cost savings
  - 5,184 reactions per run
- Comprehensive, 96-assay qPCR panel for UTI, STI, and wound infections
  - Broadens range of detection for pathogens and antibiotic resistance genes
  - Analytical LoD values of 50–10 copies per reaction
- Alien spike-in control ensures qPCR accuracy
  - Detects inhibitors
  - Prevents false negatives



that's  
**GOOD**  
science!®